Full Text View
Tabular View
No Study Results Posted
Related Studies
Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention
The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by University of Michigan.
Recruitment status was  Recruiting
Study NCT00189124   Information provided by University of Michigan

First Received on September 13, 2005.   Last Updated on February 22, 2006   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Systemic Lupus Erythematosus
Additional conditions recognized in this trial
Coronary Artery Disease
Coronary Disease
Lupus Erythematosus, Systemic
Myocardial Ischemia
More general conditions related to this trial
Arterial Occlusive Diseases
Arteriosclerosis
Autoimmune Diseases
Cardiovascular Diseases
Connective Tissue Diseases
Heart Diseases
Immune System Diseases
Vascular Diseases
Interventions listed in this trial
Dehydroepiandrosterone (DHEA)
Additional drug interventions recognized in this trial
Dehydroepiandrosterone
More general drug interventions related to this trial
Adjuvants, Immunologic
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
University of Michigan
Arthritis Foundation


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services